Dr. Jijun CHENG – General Manager, Guangzhou Curegenix Inc.
Dr. Jijun Cheng, is currently General Manager at Guangzhou Curegenix, a clinical-stage company. He held prior senior positions at Shanghai Genechem, Chengdu Hinova, Shanghai LIDE Biotech, and was a Research Scientist at Eli Lilly, where he has been engaged in new drug discovery and development in cancer, multi-organ fibrosis, and metabolic diseases, including small molecules, antibodies and immune-cell therapy. He had his Ph.D at the University of Kentucky, and was an Associate Research Scientist at Yale University, working on cancer biology, cell cycle, epigenetics and stem cell biology. He has over 30 publications in Cell, Cell Reports, Nature Communications. He is the inventor of CRISPR-cas9 Molecular Chipper, gene-editing technology. He played pivotol roles in investigational or marketed drugs, including CGX-1321, ICON-1, Abemaciclib, ACH-702, and TP-168.